Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215

Viral populations in a human immunodeficiency virus type 1 (HIV-1)-infected individual behave as a quasispecies with a rated distribution of fitness variants. Fitness distributions in naturally occurring viral populations have been difficult to study due to the lack of markers for individual virus clones and complicating inter- and intrahost factors like the presence of multiple cell types with distinct tropisms, differences in route of transmission, and intervening immunity. Here, we quantitated the relative fitness in vivo of three subpopulations of HIV-1 marked by mutations at codons 41 and 215 of reverse transcriptase (RT) directly related to zidovudine resistance in an untreated individual who was infected by a zidovudine-resistant strain transmitted from a donor on therapy. The transmission event did not have a substantial impact on the distribution of mutants within the dominant virus population replicating to high levels in the recipient. The evolution of the RT gene was monitored for 20 months. All 102 clones obtained from the donor and the recipient at the different time points contained the M41L mutation, which is associated with a fourfold reduction in zidovudine sensitivity. The leucine at position 41 was stable, although it was encoded by TTG and CTG triplets that fluctuated in abundance partially due to founder effects of clones with nonsilent mutations at codon 215. Of the three subpopulations in the patient, distinguished by a tyrosine (TAC), aspartic acid (GAC), or serine (TCC) at the 215 position of RT, the relative fitness of the GAC variant was calculated to be 10 to 25% higher than the initial TAC variant, and the relative fitness of the TCC variant was 1% higher than that of the GAC variant. Similar to other RNA viruses, lentivirus populations like HIV-1 in patients with a high virus load apparently consist of a broader spectrum of fitness variants than the 1 to 2% fitness difference sufficient for significant replicative advantage.

[1]  C. Kuiken,et al.  Similarity in env and gag genes between genomic RNAs of human immunodeficiency virus type 1 (HIV-1) from mother and infant is unrelated to time of HIV-1 RNA positivity in the child , 1995, Journal of virology.

[2]  D. van Strijp,et al.  Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. , 1993, Journal of virological methods.

[3]  S. Elena,et al.  Subclonal components of consensus fitness in an RNA virus clone , 1994, Journal of virology.

[4]  J. Kaldor,et al.  Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. , 1996, The Journal of infectious diseases.

[5]  J JongdeJ.,et al.  Zidovudine-resistente HIV-stammen bij onbehandelde intraveneuze-drugsgebruikers en homoseksuele mannen in Amsterdam geinfecteerd in 1996 , 1997 .

[6]  C. Kuiken,et al.  Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population , 1995, Journal of virology.

[7]  Lin Chao,et al.  Fitness of RNA virus decreased by Muller's ratchet , 1990, Nature.

[8]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[9]  C. Boucher,et al.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Goudsmit,et al.  Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. , 1988, AIDS.

[11]  E. Domingo,et al.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy , 1995, Journal of virology.

[12]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[13]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[14]  F. de Wolf,et al.  Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. , 1995, The Journal of infectious diseases.

[15]  J. Goudsmit,et al.  Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. , 1987, British medical journal.

[16]  J. Holland,et al.  Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses , 1991, Journal of virology.

[17]  D. Ho,et al.  Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Elena,et al.  Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells , 1995, Journal of virology.

[19]  B. Larder,et al.  Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy , 1990, The Lancet.

[20]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[21]  S. Elena,et al.  Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness , 1995, Journal of virology.

[22]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[23]  A S Perelson,et al.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.

[24]  F. McCutchan,et al.  Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. , 1993, The New England journal of medicine.

[25]  G. Angarano,et al.  Transmission of zidovudine-resistant HIV-1 through heterosexual contacts. , 1994, AIDS.

[26]  B. Larder,et al.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[28]  S. Elena,et al.  RNA virus quasispecies: significance for viral disease and epidemiology. , 1994, Infectious agents and disease.

[29]  B. Larder,et al.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. , 1992, The Journal of infectious diseases.

[30]  B. Berkhout,et al.  Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins. , 1996, Antiviral research.

[31]  M. Uhlén,et al.  Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants. , 1994, The Journal of infectious diseases.

[32]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[33]  C. Boucher,et al.  Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. , 1995, BioTechniques.